177 results on '"Humrich, Jens"'
Search Results
2. Metabolomic signature identifies HDL and apolipoproteins as potential biomarker for systemic sclerosis with interstitial lung disease
3. Autoimmune pre-disease
4. Autoantibodies targeting GPCRs and RAS-related molecules associate with COVID-19 severity
5. Nuclear antigen–reactive CD4+ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys
6. Regulatory T cells inhibit autoantigen-specific CD4+ T cell responses in lupus-prone NZB/W F1 mice
7. Autoantibodies against the chemokine receptor 3 predict cardiovascular risk
8. Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial
9. Identification and characterization of antigen-specific CD4+ T cells targeting renally expressed antigens in human lupus nephritis with two independent methods
10. When natural antibodies become pathogenic: autoantibodies targeted against G protein-coupled receptors in the pathogenesis of systemic sclerosis
11. Regulatory T cells inhibit autoantigen-specific CD4+ T cell responses in lupus-prone NZB/W F1 mice.
12. List of Contributors
13. Antibodies Against ENA (Sm, RNP, SSA, SSB)
14. Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus
15. GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis
16. Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus
17. Dysregulation and chronicity of pathogenic T cell responses in the pre-diseased stage of lupus
18. Increased protease-activated receptor 1 autoantibodies are associated with severe COVID-19
19. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial
20. 06.08 Low-dose il-2 therapy in refractory sle: results from a single centre phase i/iia clinical trial
21. 02.34 Enhanced conventional cd4+ t cell proliferation in sle is associated with up-regulation of microrna-182 and increased il-7 receptor signalling
22. Low-dose interleukin-2 therapy: a promising targeted therapeutic approach for systemic lupus erythematosus.
23. Homeostatic Imbalance of Regulatory and Effector T Cells Due to IL-2 Deprivation Amplifies Murine Lupus
24. Sechs Fragen an den Träger des Nils-Ilja-Richter-Preises 2022
25. Low- dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL- 2): a multicentre, doubleblind, randomised and placebo-controlled phase II trial.
26. The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity
27. Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE
28. A patient with acute-onset hemorrhagic necroses and bullae of the legs
29. Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response
30. Low-Dose IL-2 Therapy in Autoimmune and Rheumatic Diseases
31. Akutes Lungenversagen bei Granulomatose mit Polyangiitis
32. Loss of the CD25+ regulatory T cell subset in inflammatory myopathies and primary Sjogren's syndrome
33. Extracorporeal membrane oxygenation in ANCA-associated vasculitis
34. Phenotyping of Adaptive Immune Responses in Inflammatory Diseases
35. CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice
36. Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosus
37. 28 - Antibodies Against ENA (Sm, RNP, SSA, SSB)
38. O36 Low-dose IL-2 therapy modulates lymphocyte subsets that are involved in the regulation of germinal-centre reactions in patients with SLE
39. Low-dose IL-2 for patients with systemic lupus erythematosus – Authors' reply
40. Enhanced IL-7 receptor signaling in SLE promotes T-helper cell proliferation through upregulation of microRNA-182 and downregulation of FOXO1
41. IL-2 Therapy Diminishes Renal Inflammation and the Activity of Kidney-Infiltrating CD4+ T Cells in Murine Lupus Nephritis
42. Evaluation of therapy-induced changes in subfoveal choroidal thickness and choriocapillary perfusion in systemic sclerosis under IIoprost-infusion therapy using optical coherence tomography and angiography
43. Mature monocyte-derived dendritic cells respond more strongly to CCL19 than to CXCL12: consequences for directional migration
44. Induction of Regulatory T-cells by Dendritic Cells Infected with Vaccinia Virus
45. Evaluation of retinal microvascular perfusion in systemic sclerosis: a case–control study
46. Loko-regionär dominante Erdheim Chester Disease (ECD)
47. Pathogenetic and Clinical Aspects of Anti-Neutrophil Cytoplasmic Autoantibody-Associated Vasculitides
48. Imbalanced levels of circulating autoantibodies targeting muscarinic acetylcholine receptors in patients with systemic lupus erythematosus and systemic sclerosis
49. IL-2 therapy reduces renal inflammation and cellular activity of intrarenal CD4+ conventional T cells in lupus prone mice with active lupus nephritis
50. Altered expression of C3a and C5a receptors in patients with rheumatic diseases
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.